Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


UT Southwestern researchers find clues to TB drug resistance

Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.

The good news: A type of blood pressure medication shows promise at overcoming some drug-resistant tuberculosis, at least in the laboratory. The bad news: The Mycobacterium tuberculosis bacterium, which causes the disease, might be resistant to treatment in more people than previously thought.

Dr. Tawanda Gumbo, associate professor of internal medicine at UT Southwestern and senior author of the studies, said the research challenges current thinking about how the TB bacterium works in the body as well as how best to kill it.

His published findings come after the Dallas County Department of Health and Human Services announced this month that while the number of TB cases diagnosed in Dallas County dropped to 195 in 2009 from 219 a year earlier, the county's rate of infection is still 1.5 times higher than the national rate.

In the first study, available online and in the April 15 edition of The Journal of Infectious Diseases, Dr. Gumbo and his colleagues used an experimental apparatus to simulate the way TB bacteria grow in the human lung. When they exposed the bacteria to drugs commonly used to treat the disease – ethambutol and isoniazid – the bacterial cells activated a cellular mechanism that pumps each drug out of the cells. The pumping action enables the rapid emergence of high-level resistance to the drugs whether administered together as well as individually, Dr. Gumbo said.

"We treat TB with multiple drugs essentially to protect each other from resistance, but yet we've been puzzled with why you find resistance to both drugs together," Dr. Gumbo said. "Our findings make sense – it is more efficient from the bacteria's viewpoint to employ the same mechanism get rid of multiple attackers, whether they strike alone or at the same time."

Resistance was drastically reduced, however, when the researchers gave the blood-pressure drug reserpine – which is known to block this pumping action – to the TB cells before administering ethambutol and isoniazid.

"There is already a known solution to this problem," Dr. Gumbo said. "Hopefully now we can reduce resistance to TB treatment drugs."

Current TB treatment uses multiple drugs simultaneously, in hopes of preventing drug resistance. The next step in his research, Dr. Gumbo said, is to test all the first-line drug treatments together with the pump blocker in humans.

If first-line drugs won't work to kill TB, the person is said to have multidrug-resistant TB and doctors proceed to second-line treatments, which are usually more expensive and more toxic and take longer to work, Dr. Gumbo said.

In Dr. Gumbo's second study, available online and in the April edition of Antimicrobial Agents and Chemotherapy, the researchers found that more people might harbor drug-resistant TB than currently believed because tests that detect the TB bacteria's resistance don't account for variations in height, weight and other factors among TB patients.

Guidelines for testing whether a person is infected with a drug-resistant TB strain were developed more than 40 years ago. They involve determining the lowest concentration of a drug that will kill at least 95 percent of the TB bacteria in a patient. The TB is said to be resistant to the drug if more than 1 percent of TB still grows at that concentration.

Dr. Gumbo said those guidelines are useful for showing trends, but are not effective for predicting how an individual will respond to therapy. Recommended drug concentrations and dosages, for example, don't account for factors such as body weight, height, race and how much food a person ate before being tested.

"Science has evolved," Dr. Gumbo said. "We have better tools now so we can do more and predict better treatment."

In the second study, he again simulated TB in the human lung and virtually simulated eight clinical trials involving 10,000 patients. The computer simulation factored in pharmacokinetics (how a body handles a drug based on heterogeneous factors) to determine how likely a dose of a given drug is to kill TB.

Dr. Gumbo's research team found that the concentrations typically used in practice are too low, leading people to think they have treatable TB, when in fact their disease might be resistant to common drugs.

"There is likely more multidrug-resistant TB than previously thought – possibly up to four times as much," Dr. Gumbo said. "That means some people may be getting underdosed with medicine weaker than the disease, and they die."

The next step, Dr. Gumbo said, is to confirm these computer-driven results in patients.

Dr. Gumbo's research is funded by a 2007 National Institutes of Health Director's New Innovator Award, which supports bold ideas from some of the nation's most innovative early-career scientists.

Other UT Southwestern researchers participating in the research were Sandirai Musuka, research associate in internal medicine, and Dr. Shashikant Srivastava, postdoctoral researcher in internal medicine. Researchers from Texas Tech University Health Sciences Center's School of Pharmacy also were involved in the study published in The Journal of Infectious Diseases.

Visit to learn more about UT Southwestern's clinical services for infectious diseases, including tuberculosis.

This news release is available on our World Wide Web home page at

To automatically receive news releases from UT Southwestern via e-mail, subscribe at

Kristen Holland Shear | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung

nachricht High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Ice shelf vibrations cause unusual waves in Antarctic atmosphere

25.10.2016 | Earth Sciences

Fluorescent holography: Upending the world of biological imaging

25.10.2016 | Power and Electrical Engineering

Etching Microstructures with Lasers

25.10.2016 | Process Engineering

More VideoLinks >>>